Antengene Corporation Limited („Antengene„, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that it will present the latest clinical data of its CD73 oral small molecule inhibitor ATG-037 and oral dual mTORC1/2 inhibitor ATG-008 in Poster Presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30th to June 3rd in Chicago, IL, the United States.
ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant melanoma patients in the ongoing STAMINA-01 trial, with one patient maintaining a partial response (PR) and remained on treatment for over 2 years without any safety concerns.
- In CPI-resistant non-small cell lung cancer (NSCLC), the combination of ATG-037 and pembrolizumab achieved an ORR of 22% and DCR of 67% in the same study.
- ATG-008, an oral dual mTORC1/2 inhibitor, in combination with toripalimab, achieved an ORR of 22.2% and DCR of 85.2% in CPI-resistant cervical cancer patients in the ongoing TORCH-2 trial.
